Aclaris Therapeutics, Inc. - Common Stock (ACRS) — AI analysis & news
Aclaris Therapeutics, Inc. - Common Stock (ACRS) stock: 10 recent news items, slightly positive aggregate sentiment, AI analysis and market context on…
Current sentiment read
Across the last 10 indexed ACRS stories, aggregate finance-aware sentiment is slightly positive (+0.19 on a -1 to +1 scale).
Latest ACRS news
- Roth/MKM initiates Atrium Therapeutics stock with buy rating By Investing.com - Investing.com UK · Investing.com UK
- Why is Atrium Therapeutics stock surging today? - Investing.com · Investing.com
- Why is Atrium Therapeutics stock surging today? By Investing.com - Investing.com India · Investing.com India
- Atrium Therapeutics raises $50 million in private placement By Investing.com - Investing.com UK · Investing.com UK
- Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating By Investing.com - Investing.com India · Investing.com India
- CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com Canada · Investing.com Canada
- CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com India · Investing.com India
- CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality - Investing.com · Investing.com
- Cathie Wood’s ARK adds to Scribe Therapeutics stock position By Investing.com - Investing.com South Africa · Investing.com South Africa
- Cathie Wood’s ARK adds to Scribe Therapeutics stock position - Investing.com India · Investing.com India
FAQ
What is the current sentiment for ACRS stock?
Aggregate finance-aware sentiment across the last 10 indexed ACRS news stories is slightly positive (+0.19 on a -1 to +1 scale).